FindTrial
Sign In

Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04686760
Enrollment
278
Registered
2020-12-29
Start date
2020-11-15
Completion date
2022-03-15
Last updated
2022-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Infection

Brief summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Interventions

DRUGNitroglycerin

2 mg/ml solution of nitroglycerin used for nebulization four hourly

Sponsors

University of Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group

Exclusion criteria

allergic to nitroglycerin sudden drop in blood pressure not given consent

Design outcomes

Primary

MeasureTime frame
ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen5-7 days
Oxygen demand5-7 days

Secondary

MeasureTime frame
Duration of hospital stay15 days

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026